65615-22-7

Upstream product

• 5884-48-0 2-(4-(benzyloxy)-3-bromophenyl)acetic acid 
• 101111-25-5 methyl 2-(4-(benzyloxy)-3-bromophenyl)acetate 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 50-00-0 formaldehyd 
• 28988-68-3 2-(4-(benzyloxy)-3-hydroxyphenyl)acetic acid 

Downstream Products

• 65615-23-8 7-(benzyloxy)-8-methoxy-1H-isochromen-3(4H)-one 
• 30413-84-4 (-)-corydalmine 
• 6877-26-5 C₂₀H₂₃NO₄ 
• 924709-09-1 C₁₇H₁₅NO₆ 
• 1429118-97-7 14-(R)-3,10-dibenzyloxy-2,9-dimethoxytetrahydroprotoberberine 
• 1429118-96-6 C₂₇H₂₇NO₄ 
• 1429118-95-5 14-(R)-10-benzyloxy-2,3-methylenedioxy-9-methoxytetrahyrdooxyprotoberberine 
• 1422431-60-4 14-(S)-10-benzyloxy-2,3-methylenedioxy-9-methoxytetrahyrdooxyprotoberberine 
• 1422431-54-6 (R)-2,10-dibenzyloxy-3,9-dimethoxytetrahydroprotoberberine 
• 1196996-62-9 (S)-2,10-dibenzyloxy-3,9-dimethoxytetrahydroprotoberberine 

Relevant academic research and scientific papers

Preparation method of isoquinoline alkaloid L-corydalmine

The invention belongs to the field of medical chemistry, and provides a preparation method of L-corydalmine or pharmaceutically acceptable salts thereof. The method comprises the following steps of: in the presence of an organic solvent, catalyzing by pal

Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors

Cocaine addiction remains a serious challenge for clinical and medical research because there is no effective pharmacological treatment. L-THP, a natural product isolated from Corydalis yanhusuo W.T. Wang, is one of the most frequently used traditional herbs to treat drug addiction in China. Our laboratory first reported that its demethylated metabolites L-ICP, L-CD, and L-CP had high affinity at dopamine D1, D2, and D5 receptors. Here we report the chemical synthesis of these metabolites and other derivatives and their binding affinities at dopamine receptors. The synthesis of these bioactive metabolites will allow further in vivo study of their potential in treating cocaine addiction.

DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF

The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.

DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF

The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.

HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The pr

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile

An effective and rapid method for the microwave-assisted preparation of the key intermediate for the total synthesis of tetrahydroprotoberberines (THPBs) including l-stepholidine (l-SPD) was developed. Thirty-one THPB derivatives with diverse substituents on A and D ring were synthesized, and their binding affinity to dopamine D1, D2 and serotonin 5-HT 1A and 5-HT2A receptors were determined. Compounds 18k and 18m were identified as partial agonists at the D1 receptor with Ki values of 50 and 6.3 nM, while both compounds act as D2 receptor antagonists (Ki = 305 and 145 nM, respectively) and 5-HT1A receptor full agonists (Ki = 149 and 908 nM, respectively). These two THPBs compounds exerted antipsychotic actions in animal models. Further electrophysiological studies employing single-unit recording in intact animals demonstrated that 18k-excited dopaminergic (DA) neurons are associated with its 5-HT1A receptor agonistic activity. These results suggest that these two compounds targeted to multiple neurotransmitter receptors may present novel lead drugs with new pharmacological profiles for the treatment of schizophrenia.

Enantioselective total synthesis of (-)-(S)-stepholidine

(Chemical Equation Presented) Enantioselective total synthesis of (-)-(S)-stepholidine, a drug candidate for the treatment of schizophrenia and/or drug abuse, is described. Asymmetric transfer hydrogenation of imines with use of Noyori's catalyst was used